{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-22-000140","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.873585+00:00","generated_at":"2026-06-21T05:06:40.969279+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Ligand increases base salary and target bonus for President/COO and CFO","bullets":["Matthew Korenberg (President & COO) base salary set at $540,000 with 50% target bonus.","Octavio Espinoza (CFO) base salary set at $400,000 with 40% target bonus.","Changes effective December 5, 2022, tied to recent promotions to these roles."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-22-000140","json":"https://secwatch.observer/filing/0000886163-22-000140.json","markdown":"https://secwatch.observer/filing/0000886163-22-000140.md","text":"https://secwatch.observer/filing/0000886163-22-000140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000140/0000886163-22-000140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000140/lgnd-20221213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:06:40.969279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}